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ABSTRACT
Otto Warburg observed that cancer cells derived their energy from aerobic 
glycolysis by converting glucose to lactate. This mechanism is in opposition to the 
higher energy requirements of cancer cells because oxidative phosphorylation 
(OxPhos) produces more ATP from glucose. Warburg hypothesized that this 
phenomenon occurs due to the malfunction of mitochondria in cancer cells. The 
rediscovery of Warburg’s hypothesis coincided with the discovery of mitochondrial 
tumor suppressor genes that may conform to Warburg’s hypothesis along with the 
demonstrated negative impact of HIF-1 on PDH activity and the activation of HIF-1 
by oncogenic signals such as activated AKT. This work summarizes the alterations 
in mitochondrial respiratory chain proteins that have been identified and their 
involvement in cancer. Also discussed is the fact that most of the mitochondrial 
mutations have been found in homoplasmy, indicating a positive selection during 
tumor evolution, thereby supporting their causal role.
INTRODUCTION
At the beginning of the last century, Otto Warburg 
observed that cancer cells based their energy production 
on fermentation rather than oxidation, even in the presence 
of oxygen; therefore, these cells utilize aerobic glycolysis 
to derive energy from the conversion of glucose to 
lactate [1-3]. This metabolic switch from aerobic glucose 
metabolism through the respiratory chain to aerobic 
glycolysis is typical of cancer cells, and was named the 
Warburg effect in honor of its discoverer. This mechanism 
is in opposition to the higher energy requirements of 
cancer cells because oxidative phosphorylation (OxPhos) 
produces more ATP from glucose [4]. The large energy 
requirements of the constantly growing cancer cells render 
this phenomenon an apparent paradox. As a consequence, 
Warburg deduced that this change from OxPhos (normal 
cells) to glycolysis (cancer cells) may be a consequence of 
mitochondrial dysfunction, leaving cancer cells no other 
path for producing energy [3]. This led to the hypothesis 
described in the Warburg theory of cancer, which 
postulated that the driver of tumorigenesis is defective 
cellular respiration, which in turn is caused by defective 
mitochondrial function [1-3]. However, other possibilities 
exist. For example, the hypoxic conditions that are present 
in many solid tumors may not satisfy their requirements 
for oxygen, permitting the cancer cells to switch off 
OxPhos and favor activation of glycolysis. Oncogene 
activation and/or tumor suppressor gene inactivation may 
also produce an increase in glycolytic proteins [4]. 
Many researchers consider the reduction of 
OxPhos to be a universal feature of cancer cells. Indeed, 
mitochondria from tumor and normal cells are different 
both functionally and morphologically. However, there 
are reports of cancer cells with normal or even increased 
respiratory activity, which are in apparent contradiction 
to the Warburg hypothesis [5]. To explain this paradox, 
Smolkova et al. (2010) proposed a hypothesis that 
describes cancer progression as waves of differential gene 
expression [6]. In this model, the initial waves would be 
characterized by mitochondrial function suppression with 
stimulated glycolysis and acquisition of a typical Warburg 
phenotype. Subsequent waves would be characterized by 
the recovery of OxPhos after glutamine becomes the main 
source for both energy production and anabolic processes. 
This dependence on glutamine has been observed for 
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many cancer cells [7]. In this manner, cancer cells can 
modify their metabolism to extract energy from both 
glutamine and glucose [8]. The Warburg effect, therefore, 
should be considered as only one of the changes that 
occur in cancer cell metabolism. For example, breast and 
colorectal cancer cells exhibit a Warburg phenotype due to 
their high glucose consumption and deregulated OxPhos 
[9, 10]. However, some tumor-derived cell lines (HL60, 
HeLa, U937) make use of mitochondrial respiration to 
support their growth [11]. Depending on the environment, 
these cells can modify their metabolism from glycolysis to 
respiration, showing a high level of plasticity. In addition, 
a Warburg effect has also been detected in normal cells. 
Therefore, the Warburg effect is not a cause of cancer, 
but a common response of cells to certain environmental 
conditions [12, 13].
Hypoxia is considered to be one of the main factors 
in the switch between glycolysis and respiration. Low 
O2 availability impairs OxPhos due to its role as a final 
acceptor in the mitochondrial electron transport chain 
(mETC) [14, 15]. The adaptation of a cell to hypoxia is 
highly dependent on the expression and stabilization of the 
protein Hypoxia Inducing Factor-a (HIF-a). The two main 
isoforms of this protein that are involved in the regulation 
of hypoxia, HIF-1a and HIF-2a, are constitutively 
expressed during both normoxia and hypoxia [16]. 
However, under normoxic conditions, HIF-a is post-
translationally hydroxylated by two different proteins: 
Prolyl-Hydroxylase Domain (PHD) and Factor Inhibiting 
HIF (FIH), which marks the protein for its subsequent 
degradation [17, 18]. PHD has been shown to be inhibited 
by succinate, one of the products of the tricarboxylic 
acid (TCA) cycle that occurs in the mitochondrial matrix 
[19]. Consequently, under hypoxic conditions, there 
is an increase in succinate levels, PHD is inhibited and 
HIF-a is stabilized. In addition, ROS production also can 
inhibit PHD, thereby contributing to HIF-a stabilization 
[20]. Elevated HIF-1a levels in rapidly growing cells, 
such as embryonic cells and tumors, not only stimulate 
glycolysis, but also restrict mitochondrial respiration by 
inhibiting mitochondrial pyruvate dehydrogenase (PDH), 
thus reducing pyruvate flux into the tricarboxylic acid 
(TCA) cycle [21, 22]. Because the TCA cycle is the origin 
of NADH and succinate, which are electron donors for 
Complexes I and II, respectively, OxPhos is also inhibited. 
Adaptation to hypoxia, and also the return to normoxic 
conditions, must be finely regulated. In this way, when O2 
levels return to normal, there is a decrease in succinate 
levels. Therefore, PHD is no longer inhibited, which leads 
to destabilization of HIF-a [23]. Inadequate regulation 
of hypoxia is an important event in the acquisition of a 
malignant phenotype, and demonstrates the importance of 
proper regulation of OxPhos.
THE OXPHOS MACHINERY
This finely tuned system is composed of two 
different and separate sets of reactions that allow ATP 
synthesis (Figure 1). The first is the mtETC, which is 
composed of four different complexes (I, II, III and IV) 
that are anchored to the mitochondrial inner membrane, 
and cytochrome c [24-26]. Together, these proteins are 
responsible for electron transport from NADH or succinate 
to oxygen, translocating protons from the matrix to the 
intermembrane space of mitochondria. This allows the 
creation of an electrochemical gradient that is exploited by 
the second complex, ATP synthase, to produce ATP from 
ADP when the protons enter again into the mitochondrial 
matrix through this complex [27]. Both electron transfer 
and proton translocation are the main effects of the 
mtETC, although other products are synthesized as side 
reactions. Approximately 1-2% of all of the oxygen that is 
used in respiration leaks out as superoxide (O2
-) radicals 
and other reactive oxygen species (ROS) [28]. These 
highly reactive molecules must be neutralized by enzymes, 
such as superoxide dismutase or catalase, to diminish their 
negative effects [29]. However, under stressed conditions, 
the amount of ROS may increase and produce alterations 
in mitochondrial complexes due to undesirable reactions 
with some of the complexes [30]. In addition, ROS can 
also react with lipids such as cardiolipin, a mitochondrial 
phospholipid essential for the correct assembly and 
activity of complexes I, III and IV [31]. However, the 
long-term dramatic consequences induced by ROS are 
alterations in mitochondrial DNA (mtDNA). 
The mitochondrial genome encodes 13 polypeptides 
for OxPhos and 24 genes for tRNA and rRNA [32]. It 
has been estimated that the susceptibility of mtDNA to 
damage is approximately 10-fold higher than of nuclear 
DNA, due to the absence of histone-protection and 
its direct exposure to ROS that are generated during 
OxPhos [33, 34]. In addition, mtDNA replication by 
DNA polymerase γ occurs with lower fidelity than with 
nuclear DNA, due to mtDNA’s inferior proof-reading 
function [35]. It is known that oxidative damage to DNA 
induces two different types of transitions: T>C and G>A; 
therefore, it is reasonable to expect a higher frequency 
of these mutations in mtDNA after ROS insult [36]. 
Therefore, because parts of the complexes I, III, IV and V 
are encoded by the mitochondrial genome, damage to the 
mitochondrial genome can alter OxPhos and contribute to 
malignant transformation. Indeed, mtDNA mutations are 
associated with a wide variety of cancers such as thyroid, 
colon, ovary, breast, prostate, liver, pancreas, brain, lung 
and gastric carcinomas [37-39] (Tables 1 and 2). Many of 
the mutations in mtDNA have been detected in the D-loop, 
a non-coding region of the mitochondrial genome that 
is involved in DNA replication and RNA transcription. 
These mutations have been detected in a high number of 
tumors [38]. Furthermore, mutations in the coding regions 
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of mtDNA have also been widely described in cancer. 
Approximately 600 different mutations affecting Complex 
I alone have been described in different cancers [38], 
making the analysis of each of these mutations and their 
contribution to cancer progression difficult. To complicate 
the issue even further, a normal cell can harbor multiple 
mtDNA mutations with no apparent abnormal phenotype. 
An individual cell contains multiple mitochondria, 
and each mitochondrion can possess up to 10 copies of 
mtDNA [29]. This implies that when mutations occur in 
mtDNA, the mutations must reach a threshold to exhibit 
a significant effect. Indeed, more than 70% of all tumor-
specific mutations have also been detected in control 
populations [40]. Thus, at least 60% of all mitochondria 
in a cell would have a specific mutation [29]. However, 
many cancer-related mutations in mtDNA appear in 
homoplasmy (all mtDNA copies are identical), suggesting 
that they are positively selected during tumor evolution. 
This effect suggests that if a specific mutation occurs in 
the germline, this mtDNA modification could induce the 
appearance of tumors in offspring [29]. However, the 
lack of these mutations in tumors suggests that mtDNA 
mutations appear as a consequence of oxidative stress and 
cell division. 
Sequencing of tumor cell mtDNA has identified 
mutations in at least one of the 37 genes encoded by 
the mitochondrial genome [41]. Most of the cells that 
were examined exhibited decreased OxPhos, which was 
compensated for by an increase in glycolysis. This review 
will focus on proteins that are members of each of the 
OxPhos complexes, whose mutations have been described 
to be a cause, and not mere, of cancer progression due 
to a defect in OxPhos that can induce the Warburg 
phenotype (Tables 1 and 2). To understand the specific 
effects of a mutation, or the contribution of mitochondria 
to the acquisition of a malignant phenotype, cybrids have 
emerged as a useful strategy that can be used to analyze 
the role of mitochondria and their alterations in cancer 
progression to show that alterations other than those in 
nuclear DNA are involved in promoting cell malignancy. 
These cybrids are generated by fusing whole cells with 
enucleated cells (also called cytoplasts).
Table 1: Mutations in Complex I that are related to changes in tumorigenic properties




m.3308T>C M1T Protumorigenic Homoplasmy Colorectal cancer; Oncocytoma [56]
m.3460G>A Protumorigenic Homoplasmy In vitro [55]
m.3571insC Frameshift Antitumorigenic Homoplasmy Oncocytoma, in vitro [4, 55]
m.3571insC Frameshift Protumorigenic Heteroplasmy Thyroid oncocytoma [53]
mtND2
m.4605A>G Protumorigenic Homoplasmy Head & neck squamous cell carcinomas [33]
m.4831G>A G121D Protumorigenic Homoplasmy Head & neck squamous cell carcinomas [33]
m.4776G>A A→T Protumorigenic Homoplasmy Head & neck squamous cell carcinomas [58]
mtND3 m.10398A>G T114A Protumorigenic N.D. Breast cancer [59]
mtND4 m.12084C>T Protumorigenic Homoplasmy MDA-MB-231 [60]
mtND5
m.12418insA Frameshift Protumorigenic Heteroplasmy & Homoplasmy Colorectal cancer
[56, 
61]
m.13966A>G Protumorigenic N.D. MDA-MB-231 [60]
mtND6
m.14111insC* Frameshift Protumorigenic Homoplasmy Lewis lung carcinoma [45]
m.14223G>A# P25L Protumorigenic Homoplasmy Lewis lung carcinoma [45, 63, 64]
mtND4L
m.10563T>C Protumorigenic Homoplasmy Colorectal cancer [56]
m.10695G>A A76T Protumorigenic N.D. Head & neck squamous cell carcinomas [33]
NDUFB1 R81N Protumorigenic Heterozygosis Oncocytoma [65]
NDUFB6 E8V Protumorigenic Heterozygosis Oncocytoma [65]
NDUFA12 I134Δ Protumorigenic Heterozygosis Oncocytoma [65]
*: assigned as m.13885insC; #: assigned as m.13997G>A. Both mtDNA positions correspond to mtND5 according to 
MITOMAP and NCBI databases, while P25L is correctly assigned to the mtND6 gene.
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COMPLEX I
This complex, also known as NADH:ubiquinone 
oxidoreductase, is responsible for NADH oxidation and 
promotes electron transfer in OxPhos. Complex I removes 
two electrons from NADH to facilitate the reduction of 
ubiquinone to ubiquinol. It is composed of 45 subunits 
in mammals, 14 of which constitute the core of the 
complex, which is sufficient for energy transduction [24]. 
The others are considered as accessory or supernumerary 
subunits. This complex is located in the mitochondrial 
inner membrane, with a recently solved L-shaped structure 
that protrudes into the matrix [42]. Complex I can be 
divided into two different modules: an N-module that 
is responsible for NADH binding and oxidation, and a 
Q-module that is responsible for proton pumping. Seven 
hydrophobic proteins of the Q-module (mtND1 to mtND6 
and mtND4L) are encoded by mitochondrial DNA and are 
embedded in the mitochondrial inner membrane. The other 
7 proteins of the core are encoded by nuclear DNA; three 
of them belong to the N-module (NDUFV1, NDUFV2 and 
NDUFS1), while the remainder belong to the Q-module 
(NDUFS2, NDUFS3, NDUFS7 and NDUFS8) [24]. All 
of the nuclear-encoded proteins are hydrophilic and are 
directed toward the mitochondrial matrix. 
A deficiency in this complex has been connected 
to some human disorders, such as myopathy or 
neurodegenerative disorders [24, 43]. Because Complex I 
subunits are encoded by mtDNA or nuclear DNA (nDNA), 
these diseases may be attributed to mutations in at least 
one of the two genomes. Mutations that diminish the 
performance of Complex I have been described in all of 
the core units and in some of the supernumerary subunits, 
and are the causes of different disorders [44]. However, 
experiments with cybrids have shown that pathogenic 
mutations in Complex I that are involved in cancer 
progression are derived from mutations in mtDNA [45]. 
These mutations induce a change in tumor progression due 
to an impairment of Complex I.
Most of the mutations related to cancer tend to be 
homoplasmic [37, 46]. Two different types of mtDNA 
mutations have been described. The first type, which 
includes most of the described mutations, is comprised of 
a neutral or protumorigenic mutation that increases tumor 
growth. For example, some mtDNA mutations in Complex 
I subunits have been associated with glioblastoma, colon 
carcinoma and renal oncocytomas [37, 47, 48]. However, 
other mtDNA mutations have been associated with the 
arrest of tumor growth because the cells cannot acquire 
the advantageous Warburg profile [4]. These opposing 
effects of mtDNA mutations, both protumorigenic 
or antitumorigenic, depend on the percentage of 
mitochondrial heteroplasmy (more than one mtDNA 
genome), the effect of these mutations in Complex I 
subversion and the nuclear background. 
The tumors that are most frequently associated with 
mutations in Complex I are oncocytomas [37, 49, 50]. 
These tumors are derived from epithelial tissue and usually 
appear in endocrine and exocrine organs. They are usually 
described as benign with low invasiveness. Histological 
analysis of these tumors revealed a hyperproliferation of 
altered mitochondria, which suggested a dysfunction that 
is linked to mutations in different subunits of Complex 
I [4, 51]. The most typical mutations related to this 
oncocytic phenotype have been described for the mtND1 
protein, although mtND4 and mtND5 mutations, which 
are usually frameshift and nonsense mutations, have 
also been associated with this tumor [49, 52, 53]. It has 
been shown that when one of the subunits is mutated, the 
entire complex is destabilized, with lower protein levels 
of other subunits [31, 54]. It is likely that several subunits 
of Complex I are required to allow for its proper assembly 
Table 2: Mutations in Complexes III, IV and V that are related to changes in tumorigenic properties
Subunit Mutation Amino acid substitution Properties DNA homogeneity Tumor Ref
Mt-Cyb
m.15342insT Frameshift Protumorigenic Homoplasmy Colorectal cancer [37]
m.15557G>A E271K Protumorigenic Heteroplasmy Thyroid oncocytoma [53]
∆4-cytb Frameshift Heteroplasmy [90]
m.15642-15662del Frameshift Protumorigenic N.D. Primary bladder tumors [91]
MTCO1
m.6124T>C M74T Protumorigenic Heteroplasmy Prostate cancer cells [104]
m.6267A>G A122T Protumorigenic Homoplasmy & Heteroplasmy
breast, colon, pancre-
atic & prostate cancer 
cells
[103]
m.6277A>G G125D N.D. Homoplasmy Prostate cancer cells [105]
m.7275T>C S458P N.D. Homoplasmy Prostate cancer cells [105]
mtATP6
m.8860G>A Protumorigenic Homoplasmy Breast cancer [109]
m.8993T>G L156R Protumorigenic Homoplasmy In vitro [110]
m.9176T>C L217P Protumorigenic Homoplasmy In vitro [110]
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and degradation of all of the subunits may occur if only 
one is lacking. Previous studies on 30 oncocytic thyroid 
samples with mtDNA mutations showed that 25 tumors 
exhibited at least one Complex I subunit mutation [52]. 
A comparative analysis between renal oncocytomas and 
clear cell renal cell carcinomas showed that only the 
oncocytomas had mutations in mtDNA genes that code 
for Complex I subunits [37].
Despite the clear connection between these 
mutations and the appearance of an oncocytic tumor, in 
most cases there are few studies that explain the role of 
a specific mutation. One reason for this lack of studies 
might be that the effects appear redundant, resulting in a 
non-functional Complex I.
mtND1
This protein connects the hydrophilic core, where 
NADH is oxidized, and the hydrophobic core, which 
allows electron transport to ubiquinone. Therefore, 
any mutation here would critically affect Complex I 
functionality. Thus, some of the mutations described for 
mtND1 exhibited protumorigenic properties, while others 
exhibited antitumorigenic properties. 
The homoplasmic mutation m.3460G>A, which has 
a minimal effect on Complex I activity, was introduced 
in tumor cells to analyze osteosarcoma progression [55]. 
However, there were no significant changes in cell growth, 
perhaps due to the nuclear background. Therefore, this 
mutation could be protumorigenic because the increase in 
ROS levels and the higher resistance to apoptosis induced. 
Another mutation in colorectal cancer, m.3308T>C, 
appears in homoplasmy, suggesting a selective growth 
advantage during tumor evolution [56]. 
However, the m.3571insC mutation, which 
appears frequently in oncocytomas, behaved as a tumor 
suppressor mutation, inhibiting tumor growth when it 
was tested under homoplasmic conditions [4, 53, 55]. 
This mutation was described in the oncocytic thyroid 
cell line XTC.UC1, and induces a severe alteration of the 
complex due to the insertion of a premature stop codon at 
position 101 [53]. As a consequence, these cells exhibit 
defects in Complex I, and, by extension, in OxPhos, that 
cause an imbalance in the TCA cycle, yielding a higher 
amount of α-ketoglutarate, which is a substrate for PHD 
[57]. In addition, ATP synthesis and oxygen consumption 
suffered a large decrease relative to control cells. As a 
consequence, HIF-1a is destabilized, being tumor growth 
arrested. Thus, it has been shown that allotypic Complex 
I complementation allows HIF-1a stabilization and the 
recovery of tumorigenic potential [4]. However, a full 
deficiency in Complex I results in HIF-a stabilization, 
suggesting that the lack of Complex I suppresses oxidative 
stress, while other mutations that only reduce its efficiency 
produce an increase in ROS production. 
mtND2
In head and neck squamous cell carcinomas, two 
different mutations in the mtND2 gene, m.4605A>G 
and m.4831G>A, were identified, and their roles in 
tumorigenesis were studied [33]. To accomplish this, 
the authors created a nuclear-encoded version of this 
gene (nND2) with a signal that allows for its transport to 
Figure 1: Schematic representation of the main elements of the mitochondrial respiratory chain.
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mitochondria. HeLa cells were chosen for transfection 
studies because these cells have no mutations in the 
mtND2 gene. Both mutations induced an increase in 
ROS production and aerobic glycolysis rate with HIF-
1a stabilization, resulting in higher tumorigenicity. 
In addition, expression of mutated nND2 in head and 
neck squamous cancer cell line O19 exhibited a higher 
number of colonies of O19 cells that expressed wild-type 
nND2. Another study analyzed the mutation m.4776G>A 
in HeLa, OKF6 and O19 cells transfected with this 
mutated mtND2 [58]. Similar to the other two mutations, 
m.4776G>A induced HIF-1a upregulation. Xenografted 
tumors from HeLa cells that were stably transfected with 
m.4776G>A ND2 had a higher growth rate than HeLa 
WT cells [58]. In addition, the authors demonstrated that 
an increased production of pyruvate in cells expressing 
the mutant mtND2 was related to an increase in PDK2, 
a kinase that phosphorylates and inactivates Pyruvate 
Dehydrogenase (PDH), leading to increased ROS 
production and contributing to HIF-1a stabilization.
mtND3
In this case, the mutation m.10398G>A has been 
shown to be associated with an increased risk of breast 
cancer in two different studies, one of a European 
American female, and the other of Jewish females [59]. 
This position in the mitochondrial genome is highly 
polymorphic, and depending on the ethnic derivation, 
studies concerning its role in breast cancer show an 
increased risk or no effect at all. This suggests again that 
other changes are required to promote cancer progression. 
mtND4
MDA-MB-231 cells, which are derived from 
human breast carcinoma, are characterized by a high 
metastatic potential. To analyze the possible contribution 
of nuclear or mitochondrial mutations to this metastatic 
phenotype, mitochondria were extracted from them to 
obtain the ρ0 MDA-MB-231 cell line [60]. Cybrids were 
obtained from this cell line using purified mitochondria 
from HeLa cells that were previously modified with fetal 
mitochondria that provided a normal respiratory function. 
As controls, cybrids were also generated with MDA-
MB-231 mitochondria and ρ0 MDA-MB-231 cells. Thus, 
two different MDA-MB-231 cells were generated. The 
first can be considered to be the wild type because of the 
presence of the original mitochondria. The other cell line, 
231mtFt, contains only normal mitochondria. As a result 
of this change in the mitochondrial population, 231mtFt 
cells exhibited a significant decrease (but not suppression) 
in their metastatic potentials, showing that changes in 
mtDNA are partially responsible for this phenotype. Two 
mismatch mutations were present in mtDNA from MDA-
MB-231: m.12084C>T, which affects the mtND4 subunit, 
and m.13966A>G, which affects the mtND5 subunit. It 
should be noted that the observed phenotype can be the 
sum of both mutations, or the effect of a single one.
mtND5
The frameshift mutation m.12418insA causes 
a disruption to the mtND5 subunit. This change has 
been detected as a heteroplasmic mutation in cells from 
colorectal cancer [56]. The C8T cell line, which in vitro 
resembles the heteroplasmic condition, exhibited an 
increase in tumorigenic properties compared to 143B, a 
human osteosarcoma-derived cell line, despite the lack 
of a functional Complex I. In addition, C9T cells, which 
have the m.12418insA mutation in homoplasmy, exhibited 
the lowest tumorigenic properties, showing that, in this 
case, heteroplasmic conditions constitute an advantage 
for tumor growth [61]. These cells have a higher level 
of ROS production because of impairment in OxPhos, 
and also a higher resistance to apoptosis that is induced 
by oxidative stress. In an elegant experiment, Sharma 
et al. demonstrated an association between Complex I 
dysfunction (due to mtND5 mutations) and tumorigenicity 
[62]. To accomplish this, they used the Saccharomyces 
cerevisiae NADH protein quinone oxidoreductase (NDI1), 
a single protein that mimics the function of the entire 
Complex I, and which is encoded in the nucleus. Despite 
having a non-functional Complex I, NDI1 expression 
restored mitochondrial functions, inducing a reversal of 
tumorigenic properties and a reduction of ROS production. 
Disruption of the mtND5 subunit has been shown 
to induce oxidative stress because of an increase in 
ROS production that is due to Complex I dysfunction 
[61, 62]. This increment has been associated with AKT 
signaling though an increase in AKT phosphorylation 
and by upregulation of downstream factors such as HIF-
1a, Bcl-XL and Mcl1[62]. Activation of these genes is 
recognized as a common event in tumorigenesis. However, 
homoplasmic mutations induce a higher apoptotic 
rate, suggesting that mtDNA mutations contribute to 
tumorigenesis under heteroplasmy conditions.
mtND6
mtND6 gene mutations have been detected in Lewis 
lung carcinoma. Two different mutations, m.14111insC 
and m.14223G>A (originally assigned as m.13885insC 
and m.13997G>A) are associated with a higher metastatic 
potential [45]. The relationship between m.14111insC 
and its metastatic potential was demonstrated when, 
after exchanging mtDNA between high- and low-
metastatic mouse lung carcinoma cell lines (A11 and P29, 
respectively), these properties were also exchanged. In 
addition, metastatic properties were reverted by treating 
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cells with antioxidant agents, showing the importance of 
ROS in metastasis. The other mutation, m.14223G>A, 
has been shown to be homoplasmic and to produce higher 
levels of ROS. In addition, cells with mutations in mtND6 
contained a non-functional Complex I and an upregulated 
HIF-1a, VEGF and MCL-1, all of which were associated 
with increased tumorigenicity. 
Mice expressing mtND6 m.14223G>A exhibited 
a defective Complex I and symptoms of lactic acidosis, 
with no additional phenotypes in young individuals [63]. 
In fact, tissues from mice had a compensated phenotype 
with higher Complex I activity than that exhibited by 
homoplasmic m.14223G>A cells. In addition, ROS levels 
in mutant mice were similar to ROS levels in the WT 
mice. However, aged mice exhibited a higher incidence of 
lymphoma, although B6 mice, the nuclear donor, exhibited 
a frequent lymphoma rate, thus the mutation only acts by 
increasing this rate. In a recent paper, the authors used 
A/J mice as receptors of m.14223G>A because this strain 
has no tendency to develop lymphomas [64]. As a result, 
the lymphoma frequency was not increased in mice with 
the m.14223G>A mutation, showing that an additive effect 
between the nuclear background and mtDNA mutations 
must occur to increase the tumorigenic properties.
mtND4L
m.10563T>C has also been described in 
homoplasmic conditions in colorectal cancer cells, 
showing that this mutation confers an advantage on the 
cells during cancer progression [56]. Other mutations, 
such as m.10695G>A, have also been shown to be 
associated with tumor progression [33].
Nuclear encoded proteins
Mutations that cause a deficiency in Complex 
I have been identified in the 7 core proteins that are 
encoded by nuclear DNA and also in supernumerary 
subunits and assembly factors. However, there is a limited 
amount of data concerning the role of these mutations in 
tumorigenesis [44]. In oncocytic samples, the most typical 
tumor attributed to Complex I mutations, the 38 nuclear 
genes encoding the remainder of the subunits of this 
complex were analyzed [65]. Thus, three heterozygous 
modifications with possible effects on Complex I 
functionality were detected: the missense changes R81N 
in NDUFB1 and E8V in NDUFB6 and a deletion of three 
nucleotides erasing Ile134 in NDUFA12 [65]. These 
changes appeared with a higher frequency in oncocytic 
samples relative to control samples, suggesting a possible 
connection with the disease.
However, it should be noted that most of the 
mutations that were detected appear in heterozygosis, 
and with lower frequencies than with mtDNA mutations 
[45, 66]. This suggests that mutations in nuclear-encoded 
Complex I genes have a more deleterious effect with 
unfavorable consequences for cell viability than do 
mutations in mtDNA that usually appear in heteroplasmy. 
In fact, nDNA mutations have been linked with other 
diseases such as Leigh syndrome, cardiomyopathy or 
encephalomyopathy [24, 67].
To conclude, the role of the mutations that affect 
Complex I in mutagenesis is redundant. All of these 
mutations have similar consequences: changes in Complex 
I functionality that promote an increase in ROS production 
[68], an imbalance in the TCA cycle, inhibition of PHD 
and, consequently, HIF-a stabilization. A downstream 
transcription of hypoxia-related genes under normoxic 
conditions is one of the most common events in 
tumorigenesis.
COMPLEX II
Complex II, or succinate dehydrogenase ubiquinone-
ubiquinol reductase, is a member of the TCA cycle and 
is attached to the internal side of the mitochondrial inner 
membrane. It is the smallest complex that participates 
in OxPhos, containing only four subunits, all of which 
are encoded by nuclear DNA and are imported into the 
mitochondria where the complex is assembled after 
cofactor addition and protein folding [69]. As a member 
of the TCA cycle, it is involved in succinate oxidation 
to fumarate and is also an electron donor to ubiquinone 
in OxPhos, but not as a proton pump through the inner 
mitochondrial membrane. The two catalytic subunits are 
SDHA, a flavoprotein, and SDHB, an iron-sulfur protein, 
which are bound to the inner mitochondrial membrane 
through interactions with the other two components of 
the complex, SDHC and SDHD. Both membrane subunits 
constitute the heme-protein cytochrome b in this complex 
that promotes its interaction with ubiquinone for electron 
transfer in OxPhos.
A large number of mutations within the four 
components of this Complex have been indirectly 
linked to different types of tumors, although most of 
the existing studies do not focus on specific mutations. 
Mutations in this complex have been mainly associated 
with pheochromocytomas and paragangliomas, tumors 
of the parasympathetic and sympathetic nervous system 
that affect the adrenal gland and the carotid body [69]. 
Indeed, patients with these types of tumors are evaluated 
clinically to detect mutations in proteins of Complex II. At 
least 30% of all these tumors are derived from a germline 
mutation in one of the susceptibility genes. Mutations in 
the SDHC and SDHD subunits are associated with head 
and neck paragangliomas, while mutations in the SDHB 
subunit have been linked to malignant paragangliomas. 
Mutations in SDHA and SDHB have been detected also in 
gastrointestinal stromal tumors (GISTs) [70].
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SDHA
SDHA constitutes the major catalytic subunit of 
Complex II, with a covalently attached flavin adenine 
dinucleotide as a prosthetic group [71]. In addition, both 
enzyme substrates and physiological regulators bind to 
SDHA. The Sdha gene is composed of 15 different exons, 
thus rendering its analysis to detect mutations related to 
cancer difficult; thus it is not routinely analyzed [72]. 
However, 15 pathogenic mutations in SDHA have been 
described, most of them related to GISTs [25, 72]. Only 
three mutations have been described in paragangliomas 
and pheochromocytomas, the most common tumors 
that are produced by mutations in Complex II, [73]. 
These mutations, the biochemical analysis of which has 
uncovered their relationship to cancer, may have a very 
low incidence, with most of the mutations producing no 
clinical symptoms. 
SDHB
This gene has the highest mutation rate of 
all Complex II proteins, causing extra-adrenal 
paragangliomas, adrenal pheochromocytomas, head and 
neck paragangliomas and papillary thyroid cancer [25, 
69]. Germline mutations in this protein are associated with 
a higher risk of developing renal cell carcinoma [74]. In 
addition, in the absence of KIT and PDGFRA mutations, 
both of which are characteristic of GISTs tumors, SDHB 
mutations have been related to GIST development [70]. 
Carriers of mutations in SDHB have a 25-40% probability 
of developing a tumor and a 20% probability of metastatic 
disease [25]. Indeed, mutated SDHB in tumors increase 
the risk of the appearance of malignant tumors, and have a 
poor prognosis. Paragangliomas and renal cell carcinomas 
derived from mutations in the SDHB gene had giant 
mitochondria in their cell cytoplasm [75]. 
SDHC 
SDHC constitutes a large subunit of cytochrome 
b and is anchored to the mitochondrial membrane. 
Mutations in this gene primarily produce head and 
neck paragangliomas, although some sympathetic 
paragangliomas have also been reported [76, 77]. 
However, mutated SDHC has been detected less frequently 
than mutations in SDHA or SDHB, and have a very low 
tendency toward malignant transformation [25].
In vitro experiments using NIH3T3 cells 
transformed with a mutated SDHC demonstrated both a 
higher rate of apoptosis and tumorigenicity [78]. However, 
it should be noted that transformed NIH3T3 had to be 
cultured for at least one month to increase its ability to 
form tumors after injection. This suggests that a selection 
phase occurs after cell transformation with mutant SDHC, 
with most of the cells dying because of the accumulation 
of ROS. The requirement of at least one month of survival 
for the cells in order for them to develop tumors suggests 
an SDHC-derived higher mutation rate.
SDHD
Mutations in this protein are usually associated with 
benign head and neck paragangliomas, although they also 
have been detected in sympathetic paragangliomas and 
adrenal pheochromocytomas [79]. A decreased expression 
of SDHD has also been associated with gastric and colon 
carcinomas. It has been shown that if the mutation is 
inherited only from the father, then the carriers have a 
high probability of developing tumors that are derived 
from SDHD mutations. However, experiments with Sdhd 
knockout mice demonstrated an absence of paraganglioma 
or pheochromocytoma development, suggesting that other 
mutations are required to form tumors [80].
SDHAF2 and FH
In addition to the mutations in the four proteins 
that constitute Complex II, other mutations have been 
described in proteins that are related to this complex. 
The G78R mutation in succinate dehydrogenase 
complex assembly factor 2 (SDHAF2) was identified 
in a head and neck paraganglioma [71]. SDHAF2 adds 
the FAD prosthetic group to SDHA, thus a defect in 
SDHAF2 results in a loss of Complex II function, as was 
demonstrated in yeast experiments [71]. As with SDHD, 
only mutations with a paternal origin have been associated 
with tumorigenesis [81]. Mutations in fumarate hydratase 
(FH), an enzyme in the TCA cycle that follows SDH, have 
been associated with multiple cutaneous leiomyomas, 
uterine leiomyomas and aggressive renal cell carcinomas 
[82].
In conclusion, mutations in Complex II result in 
the formation of a non-functional complex, leading to the 
accumulation of succinate that acts as an inhibitor of PHD. 
Due to the constitutive expression of HIF-a, the lack of 
active PHD produces HIF-a stabilization, and transcription 
of hypoxia-dependent genes, which is associated with a 
higher tumorigenicity potential. Thus, an activated HIF-a 
pathway has been detected in SDH-deficient tumors 
[80, 83, 84]. However, human breast cancer samples 
exhibited a low correlation with HIF-1a stabilization [85]. 
Nevertheless, there are no animal models that resemble 
the human phenotype because heterozygous animals do 
not develop cancer, and homozygosity is lethal [86, 87]. 
In addition, there are no established cell lines that are 
derived from Complex II-related tumors. Consequently, 
additional research concerning the role of Complex II in 
tumorigenicity, for example using cybrids, is required.
Oncotarget41590www.impactjournals.com/oncotarget
COMPLEX III
This complex, ubiquinol-cytochrome c reductase, 
promotes electron transfer between ubiquinol and oxidized 
cytochrome c. In its native form it is a dimeric complex 
comprised of eleven different subunits, with only the 
cytochrome b subunit (cytochrome bc1 complex subunit 
3) being coded by mtDNA [88]. To date, only cytochrome 
b has been found mutated in some diseases, and there are 
no mutations for nuclear-encoded genes [89].
Complex III is one of the main sites for superoxide 
production, thus a deficiency or malfunction at this site 
can increase ROS-associated damage. Therefore, unlike 
Complexes I and II, for which ROS production is in 
the mitochondrial matrix, Complex III can also release 
superoxide to the intermembrane space. 
 Cytochrome b
Various mutations, including deletions, frameshift 
and missense mutations, have been described in mtDNA 
genes, with most of the mutations being located outside 
of the trans-membrane domains. It has been shown that 
mutations in Complex III are also associated with a non-
functional Complex I because of its possible association 
in a respirasome supercomplex. Mutations in Complex III, 
such as the frameshift mutation m.15342insT, have been 
found also in oncocytomas[37]. The thyroid oncocytic 
follicular cell line XTC.UC1 contains a combined 
frameshift mutation in ND1 and a non-conservative 
substitution, m.15557G>A, in cytochrome b [53]. This 
mutation induced a significant decrease in complex III 
activity, although the heteroplasmy with wild-type alleles 
may be sufficient to complement the deleterious effects in 
these cells.
Cybrids with a 4-bp deletion in the cytochrome b 
gene, a mutation that has been described in Parkinson 
disease, exhibited a loss of oxygen consumption with 
ROS production under hypoxic conditions and a stabilized 
HIF-1a [90]. The overexpression of a 21-bp deletion in the 
cytochrome b gene in carcinoma cells induced an increase 
in ROS, lactate production and oxygen consumption. 
In addition, cells with this deletion have increased 
tumorigenic properties, being more invasive in murine and 
human bladder cancer models [91].
As with complex I, mutations in cytochrome b 
promote an increase in ROS levels. This increment can, 
consequently, induce stabilization of HIF-a by inhibiting 
PHD.
Cytochrome c
This small, soluble protein, is localized in the 
intermembrane space and is attached to that space in two 
different pools, loosely and tightly bound, because of its 
interaction with, among other molecules, cardiolipin [92]. 
Its primary function is to act as a one-electron carrier 
between mitochondrial complexes III and IV. However, 
it also has a role as an apoptosis triggering protein [93]. 
After induction of apoptosis, cytochrome c is released 
from the mitochondria and then interacts with Apaf-1, 
thereby initiating the caspase activation cascade [94]. 
Although some mutations in cytochrome c have 
been described (M80A, G41S, Y48H, Y48E, Y48F, 
K72A, K72W, K72G, K72R, K72E and K72L) [95], none 
of them have been demonstrated to be associated with 
cancer [96, 97]. In addition, only G41S and Y48H have 
been observed in a human disease, thrombocytopenia, a 
syndrome characterized by a low number of platelets [97]. 
Both mutations are pro-apoptotic, and lead to an increase 
in the activation of programmed cell death. None of the 
other mutations have been detected in vivo; however, they 
all exhibit antiapoptotic properties, leading to non-efficient 
apoptosome activation and, consequently, cell survival 
[95]. 
With regard to post-translational modifications, 
four residues are phosphorylated in vivo (T28, Y48, S47 
and Y97) [98]. Phosphorylation of one of these residues, 
Y48, was studied using a phosphomimetic substitution 
(Y48E), which demonstrated both a partial inhibition of 
electron transfer to complex IV and an inability to promote 
activation of caspases [99]. The authors suggested that 
cytochrome c in its phosphorylated state could act as an 
oncogenic protein because of apoptosis inhibition; to date, 
there are no biological data supporting this hypothesis. 
In addition, analysis of gastric carcinomas, colorectal 
carcinomas, breast ductal carcinomas, hepatocellular 
carcinomas, acute myelogenous leukemias and acute 
lymphoblastic leukemias detected no mutations in 
cytochrome c [96].
COMPLEX IV
This complex, which is also called Cytochrome 
c Oxidase (CcO) is the final electron acceptor in the 
mitochondrial respiratory chain. It reduces molecular 
oxygen (O2) to water with four electrons that are 
transferred from four different molecules of cytochrome c 
[100]. This complex is composed of 13 different subunits 
in mammals, and the catalytic core has three mtDNA-
encoded subunits (MTCO1, MTCO2 and MTCO3). 
The other 10 subunits, and other proteins related to the 
Complex IV assembly, are encoded by nDNA [101]. 
Nonsense mutations, deletions and heteroplasmic point 
mutations have been detected in the three mtDNA-encoded 
subunits. Regarding nuclear-encoded genes, mutations 
have been found more frequently in genes related to 
the Complex IV assembly, such as copper chaperones 
or proteins involved in heme biosynthesis. Most of the 




Mutations in MTCO1 are associated with a higher 
risk of developing prostate cancer, although these 
mutations were initially detected in colon cancer cells 
[56]. Missense mutations in MTCO1 have been detected 
in 11-12% of all prostate cancer patients [102]. Different 
models have been used to study some of the mutations 
found in the mitochondrial gene. The probable germline 
mutation m.6267A>G (A122T) is a recurrent mutation 
that appears with a higher frequency in cancer cells than in 
normal tissues [103]. This mutation affects a position that 
is critical for the interaction between MTCO1 and subunit 
III of Complex IV. Cybrids harboring this mutation 
exhibited a 50% decrease in Complex IV activity. 
Mitochondria with a heteroplasmic (50%) mutation, 
m.6124T>C (M74T) were also detected in a prostate 
tumor and were purified to generate pure wild-type or 
mutant cybrids [104]. For this mutation, the activity of 
MTCO1 decreased 29%, with a concomitant increase in 
ROS production. In addition, cybrids with this mutation 
exhibited faster growth in culture, decreased apoptotic 
rates and increased in vivo tumor growth. The last effect 
was observed when cybrid cells were injected into nude 
mice, producing larger tumors with cybrids that had the 
mutant version of MTCO1. 
Two different missense mutations found in prostate 
cancer cells, m.6277A>G and m.7275T>C, were analyzed 
functionally using the purple bacterium Rhodobacter 
sphaeroides, a model for mitochondria [105]. The 
m.7275T>C mutation, which has a S458P substitution, 
resulted in no expression of the enzyme. The G125D 
substitution induced a decrease in Complex IV activity, 
with slower electron transfer and proton leakage. However, 
there are no data for these mutations with mitochondria in 
human cells.
MTCO2 and MTCO3
Missense mutations in the MTCO2 gene are 
associated with an adverse prognostic impact in patients 
with acute myeloid leukemia [106]. In addition, other 
mutations in MTCO3 have been described that are 
associated with hepatocellular carcinoma [41].
It has been observed, that, under hypoxia conditions, 
gene transcription of the nuclear-encoded subunits I, IVi1 
and Vb were significantly reduced, suggesting that the lack 
of a functional Complex IV can also contribute to HIF-a 
stabilization [107]. In addition, a decrease in Complex IV 
activity has also been associated with an increase in ROS 
production, which is not directly due to Complex IV but 
is a result of an impairment of the entire OxPhos chain 
[27, 104]. 
COMPLEX V
This complex, ATP synthase, is not associated with 
mETC, but it can be considered as a member of OxPhos 
due to the H+ gradient that is established by Complexes I, 
II and IV that allows ATP synthesis. It can be divided into 
two different subunits, which are referred to as F0 and F1 
particles and are connected by two additional structures. 
The five subunits of F1 are nuclear-encoded, as are most 
of the F0 subunits, with the exception of two (mtATP6, 
mtATP8) that are encoded by mtDNA [108].
Regarding both mitochondrial genes, it has been 
recently shown that mtATP6 has a higher mutation 
frequency than mtATP8, at least in breast cancer [109]. 
Indeed, one mutation in mtATP6, m.A8860A>G, was 
detected in all of the cases analyzed, suggesting that this 
substitution may increase the risk of breast cancer [109]. 
Two other different pathogenic mutations have 
been characterized in mtDNA for the ATP6 gene, 
m.8993T>G and m.9176T>C, and although they have not 
been linked with cancer, they are associated with Leigh 
syndrome [110]. To analyze the possible role of both 
mutations that were originally detected in patients with 
mitochondrial encephalomyopathy [111], cybrids with 
one of these mutations were obtained by fusing enucleated 
fibroblasts from patients to one of these mitochondrial 
mutations with HeLa cells without mitochondria. Then, 
the cells were injected into nude mice to determine their 
tumorigenicity. Both mutations provided an advantage in 
early stages of tumor growth due to a decreased apoptotic 
rate and faster cell growth. It was, however, shown that 
the m.8993T>G mutation produced a 60% decrease in 
the rate of ATP synthesis [112]. In addition, it was shown 
that both mutations decreased oxygen consumption. 
Another study analyzed the role of the m.8993T>G 
mutation by introducing it into PC3 prostate cancer 
cells, and demonstrated a 7-fold increment in its tumor 
formation ability [102]. Pathogenic mtATP6 mutations 
are associated with an upregulation of fibroblast growth 
factor 1 (FGF-1) and focal adhesion kinase (FAK) [113]. 
An additional mutation in the mtATP6 gene, m.8601A>G, 
has been found in early stage breast cancer, suggesting 
that missense mutations in this gene increase the risk of 
developing tumors [114].
CONSEQUENCES OF MTDNA 
MUTATIONS IN THE CLINIC
The word “cancer” encompasses a large variety 
of diseases that are based on DNA alterations, making 
it difficult to establish general rules for treating different 
tumors. Mitochondria constitute an ideal target for clinical 
treatment due to its role as the energetic core of the cell. 
In fact, there are anti-cancer drugs (mitocans) that are 
directed against different mitochondrial elements such as 
metabolic inhibitors, ROS regulators and Hsp90 inhibitors 
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[115]. The main objective for understanding the effects 
of mitochondrial mutations on cancer progression is 
to design medical strategies to arrest tumor evolution. 
This can help to avoid treatments with undesirable side 
effects. For example, mutations in mtND4 induce acquired 
chemoresistance during paclitaxel/carboplatin treatment 
[116], suggesting that this treatment should be avoided 
in patients with mtND4 mutations. In addition, treatment 
of tumors with heteroplasmic mutations can increase the 
level of mtDNA mutations [117, 118]. The high mutagenic 
rate of mtDNA, therefore, is justification for a preliminary 
study that would focus on certain properties of the tumor. 
Mitochondrial DNA extracted from a cancer biopsy can 
be used to determine the mutations present in the mtDNA, 
allowing the design of specific treatments against the 
tumor and minimizing the side effects.
Mutations have been described in Complexes I and 
III, and to a lesser extent in Complexes II and IV, which 
promote an increase in ROS production, with HIF-a 
stabilization and activation of hypoxia signaling (Figure 
2). This similar behavior, as a result of different mutations 
in different complexes, indicates that mitochondria can 
be considered an ideal target for the design of specific 
ROS-based anticancer treatments due to the large number 
of tumors that exhibit a Warburg profile. Mutations in 
Complexes I and III can be utilized in a similar manner. 
Although cancer cells have impaired apoptosis, the 
increase in ROS production can be used to induce 
apoptosis using prodrugs that are activated by ROS [119]. 
Because tumor cells have higher ROS levels than normal, 
this type of treatment should minimize the effects on non-
tumor cells. 
Regarding Complex II, although there are some 
reports concerning the role of this complex in the 
production of ROS [120-122], the main tumorigenic effect 
of Complex II dysfunctions will be inhibition of PHD by 
the accumulated succinate. In this case, the treatment 
should be based on cell-permeable a-ketoglutarate 
derivatives that restore PHD activity, thereby preventing 
HIF-a stabilization [123]. 2-deoxy-glucose (2-D-glucose) 
is a glucose analogue that induces SDH activity with 
a decrease in succinate levels [124], allowing PHD 
Figure 2: Schematic representation of the possible contributions by the different complexes of the mitochondrial 
respiratory chain to HIF activation.
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activation and HIF-a ubiquitination. This can be useful for 
mutations that occur in a partially functional Complex II. 
Glycolysis, the main characteristic of the Warburg 
phenotype, can also be targeted using different therapeutic 
agents such as 2-D-glucose alone or in combination 
with other drugs [125]. This molecule acts by inhibiting 
hexokinase, which is the first enzyme of the glycolytic 
pathway. It has been shown that a combination of this 
molecule with metformin, which blocks Complex I 
activity, induces cell death [126, 127]. In cases of tumors 
with a severe impairment of Complex I, 2-D-glucose 
should be sufficient as treatment against these 
mitochondria. However, due to the variability of cancer, 
the treatment chosen for altered mitochondria might not be 
adequate to defeat the disease. Nevertheless, knowledge 
of the specific mtDNA mutations in a specific tumor will 
help to choose a better and more powerful treatment with 
reduced side effects.
CONCLUDING REMARKS
Most of the described mutations affecting proteins 
related to OxPhos have been found to be redundant in 
their biological effects. Generally, a single mutation 
in one of the four complexes of the mtETC induces a 
loss of function (partial or total) that disrupts OxPhos 
balance. The loss of OxPhos balance usually leads to 
lower O2 consumption [53, 57, 90, 105, 110], with some 
exceptions, such as a 21-bp deletion in cytochrome b 
[91]. This decrease is also correlated with a decrease in 
mitochondrial membrane potential, which leads to the 
dysfunction of the entire organelle [26, 31, 32, 53]. When 
this occurs, ROS and/or succinate levels rise, inhibiting 
PHD, promoting HIF-a stabilization, and inducing a 
pseudo-hypoxic response under normoxia conditions. 
However, it should be noted that these mutations occur 
in the gene-coding sequence, but a mutation in a non-
coding region, related to transcription, may have similar 
effects in tumor development because the lack of one 
of the proteins will result in a non-functional complex. 
In breast cancer cells, proteins of all of the complexes 
exhibit reduced expression from both nDNA or mtDNA 
[85, 128]. This suggests that we also need to consider 
other regions from either the nuclear or the mitochondrial 
genome that could be involved in gene transcription. In 
addition, it must be considered that the phenotype that is 
attributed to a specific mtDNA mutation can add to other 
mutations, promoting a greater tumorigenic effect. Thus, 
the pancreatic cancer cells lines CFPAC-1 and CAPAN-2 
exhibited resistance to anticancer drugs because of their 
mutations in different mtDNA proteins of the different 
complexes of OxPhos [129]. 
As has been discussed in this review, most of 
the mitochondrial mutations have been observed in 
homoplasmy, showing a positive selection during 
tumor evolution. These mutations appear to be the 
cause of unbalanced OxPhos regulation through non-
adequate hypoxia regulation or increase in ROS due to 
stressed conditions. The described mutations in proteins 
from Complex I to Complex IV (with the exception of 
cytochrome c) induce an increase in ROS production 
leading to HIF-a stabilization (Complexes I, III and IV), 
or directly induce HIF-a stabilization through inhibition 
of PHD (Complex II). Taken together, these data suggest 
that mitochondrial mutations could be the origin of the 
Warburg phenotype by way of HIF activation.
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